arrow_back Trending Legislation
Share share

Increased Funding for Sickle Cell Disease Treatment and Research

This act boosts funding for programs treating and preventing complications of sickle cell disease and other inherited blood disorders. This means better access to medical care and support for research, potentially improving the quality of life for affected individuals.
Key points
Increased funding for sickle cell disease treatment programs from $4.455 million to $8.205 million annually for fiscal years 2025-2029.
Expanded program scope to include prevention and treatment of sickle cell disease complications.
Allows for grants and cooperative agreements, potentially streamlining fund distribution.
Emphasizes the need for further research into the causes and cures for heritable blood disorders.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Print number: HR 1796
Sponsor: Rep. James, John [R-MI-10]
Process start date: 2025-03-03
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Funding for Sickle Cell Disease Treatment and Research

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 1796.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-03-03.

What are the main provisions?

Key points include:

  • Increased funding for sickle cell disease treatment programs from $4.455 million to $8.205 million annually for fiscal years 2025-2029.
  • Expanded program scope to include prevention and treatment of sickle cell disease complications.
  • Allows for grants and cooperative agreements, potentially streamlining fund distribution.
  • Emphasizes the need for further research into the causes and cures for heritable blood disorders.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. James, John [R-MI-10].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

Analysis and Potential Impact of HR 1796

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health